While biologics will drive growth in the asthma market, their prescribing will be restricted due to their high price and limited target patient population.
By Christina Vasiliou, Senior Analyst
5 May 2016
I joined Datamonitor Healthcare in early 2014, having completed an MPhil in Bioscience Enterprise at the University of C...
Read full bio
Datamonitor Healthcare forecasts the increasing availability of biologics to drive growth in the asthma market, though their prescribing will be restricted. Xolair held a unique position in the asthma market as the only approved biologic until GlaxoSmithKline’s Nucala gained US Food and Drug Administration approval in November 2015. In March 2016, Teva’s intravenous anti-interleukin-5 monoclonal antibody, Cinqair, also received US approval for use in asthma. Datamonitor Healthcare expects competition in the biologics class to increase in the foreseeable future due to the anticipated launches of a number of other interleukin inhibitors, including benralizumab and lebrikizumab, as well as the subcutaneous formulation of Cinqair. While biologics could address a high burden in the treatment of asthma, their high cost and limited target patient population, namely the small number of severe patients who are inadequately controlled on available therapies, will restrict their patient share. However, their high price will also mean that companies will see relatively high returns, despite low patient uptake.
“The cost is going to be a huge barrier to prescribing biologics. I think there is going to be a very restricted application of these new treatments.”
EU key opinion leader
Datamonitor Healthcare’s asthma: forecast uses a patient-based approach to size the asthma market opportunity across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) during 2015–24.
Get your free demo today – simply fill out the form to the right.